Cargando…
Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas
OBJECTIVES: Endometrial stromal sarcomas (ESS) are rare, accounting for < 1% of all uterine malignancies. Treatment has been guided by small case series and retrospective studies. Endocrine therapy is used in both adjuvant and metastatic settings. Aromatase inhibitors (AIs) are widely used in cli...
Autores principales: | Crowley, Fionnuala, Cadoo, Karen A., Chiang, Sarah, Mandelker, Diana L., Bajwa, Raazi, Iasonos, Alexia, Zhou, Qin C., Miller, Kathryn M., Hensley, Martee L., O'Cearbhaill, Roisin E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011013/ https://www.ncbi.nlm.nih.gov/pubmed/35434239 http://dx.doi.org/10.1016/j.gore.2022.100980 |
Ejemplares similares
-
ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment
por: Dessources, Kimberly, et al.
Publicado: (2022) -
High-Grade Transformation of Low-Grade Endometrial Stromal Sarcomas Lacking YWHAE and BCOR Genetic Abnormalities
por: Zou, Youran, et al.
Publicado: (2020) -
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
por: Boland, Julia L., et al.
Publicado: (2018) -
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
por: Navitski, Anastasia, et al.
Publicado: (2021) -
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
por: Rubinstein, Maria M., et al.
Publicado: (2023)